| Uveitis | 230 (9.9) | 97 (8.7) | | |
| Atopic dermatitis | 34 (1.5) | 10 (0.9) | | |
| Short stature, reported | 34 (1.5) | 13 (1.2) | | |
| Obesity, reported | 18 (0.9) | 10 (0.8) | | |
| Obesity, calculated (BMI SDS >3) | 17 (0.9) | 13 (1.3) | | |
| Diabetes mellitus Type 1 | 11 (0.5) | 7 (0.6) | | |
| Pain syndrome | 14 0.6) | 5 (0.4) | | |
| Hypertension | 10 (0.4) | 10 (0.8) | | |
|
| Comorbidities with female gender | Female, n (%) | Male, n (%) | p | Odd's ratio f/m |
|
|---|
| Hashimoto-Thyreoiditis | 25 (1.1) | 4 (0.4) | 0.031 | 3.0 |
| Anaemia | 13 (0.5) | 1 (0.1) | 0.043 | 6.3 |
| Hip dysplasia | 10 (0.4) | 0 | 0.0045 | † |
| Raynaud's phenomenon | 5 (0.2) | 0 | 0.045 | † |
| Macrophage activation syndrome | 5 (0.2) | 0 | 0.045 | † |
|
| Comorbidities with male gender predominance | Female, n (%) | Male, n (%) | p | Odd's ratio m/f |
|
|---|
| Asthma | 29 (1.0) | 24 (2.6) | 0.0005 | 2.6 |
| Attention deficit and hyperactivity disorder | 14 (1.3) | 5 (0.2) | 0.0001 | 5.9 |
| Psoriasis | 8 (0.3) | 11 (1.0) | 0.0175 | 2.9 |
| Short stature, calculated (lengh SDS <−2) | 123 (5.8) | 111 (10.0) | <0.0001 | 1.8 |